Effect of fully automated closed‐loop insulin delivery using faster aspart versus standard aspart on gluco‐regulatory hormones in type 2 diabetes. Issue 1 (28th September 2020)

• Record Type: Journal Article
• Authors: Herzig, David; Studer, David; Nakas, Christos T; Kuenzli, Christina; Stauffer, Thomas P; Hovorka, Roman; Bally, Lia
• Is Part Of: Diabetes, obesity & metabolism. Volume 23:Issue 1(2021)
• Page Start: 228
• Page End: 233
• Publication Date: 2020-09-28
• Subjects: insulin analogues -- incretin physiology -- insulin pump therapy -- insulin secretion -- type 2 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14185
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: We retrospectively assessed gluco‐regulatory hormones over 10 h (including two meals) of fully automated closed‐loop insulin delivery using faster (FA) versus standard insulin aspart (IAsp) in adults with type 2 diabetes [n = 15, age 59 ± 10 years, body mass index 34.5 ± 9.1 kg/m 2, glycated haemoglobin 7.7 ± 1.2% (60 ± 13 mmol/mol)]. Plasma concentration of human insulin, IAsp, C‐peptide, glucagon, glucagon‐like peptide 1, glucose‐dependent insulinotropic peptide and peptide tyrosine tyrosine were measured every 15‐30 min. Endogenous insulin secretion was calculated using C‐peptide deconvolution and exposures to hormones were compared using their mean plasma concentrations. Ten‐hour exposure of IAsp was higher with FA versus IAsp ( P = .037) in line with the 10% higher insulin requirements to achieve similar glucose control. No significant difference was found for total insulin exposure and endogenous insulin secretion. Similarly, other gluco‐regulatory hormones did not significantly differ. In conclusion, the faster pharmacokinetic profile and slightly higher aspart exposure of FA versus IAsp remained without significant effects on endogenous insulin secretion or other gluco‐regulatory hormones. Further studies are warranted to explore the metabolic and endocrine effects of novel insulins with accelerated pharmacokinetic properties.